CRL (Charles River Laboratories International) Cyclically Adjusted Revenue per Share: $73.42 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRL Charles River Laboratories International Inc CRL
70 GF Score
Price $219.40
GF Value $194.04
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Charles River Laboratories International Cyclically Adjusted Revenue per Share?

Charles River Laboratories International CRL -0.14% 70 Cyclically Adjusted Revenue per Share is $73.42 as of Mar. 2026. GuruFocus rates CRL with a GF Score™ of 70/100 and a GF Value™ of $194.04 (Modestly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Charles River Laboratories International's adjusted revenue per share for the three months ended in Mar. 2026 was $20.343. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $73.42 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Charles River Laboratories International's average Cyclically Adjusted Revenue Growth Rate was 9.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 13.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Charles River Laboratories International was 16.00% per year. The lowest was 6.30% per year. And the median was 10.20% per year.

As of today (2026-07-21), Charles River Laboratories International's current stock price is $219.40. Charles River Laboratories International's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $73.42. Charles River Laboratories International's Cyclically Adjusted PS Ratio of today is 2.99.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Charles River Laboratories International was 11.01. The lowest was 1.49. And the median was 3.99.


Charles River Laboratories International  (NYSE:CRL) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Charles River Laboratories International's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=219.40/73.42
=2.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Charles River Laboratories International was 11.01. The lowest was 1.49. And the median was 3.99.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Charles River Laboratories International Cyclically Adjusted Revenue per Share Related Terms


Charles River Laboratories International Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Charles River Laboratories International's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Charles River Laboratories International Cyclically Adjusted Revenue per Share Chart

Charles River Laboratories International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.83 52.52 59.18 65.12 71.07

Charles River Laboratories International Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.01 68.72 70.22 71.07 73.42

CRL vs RVTY, QGEN, ICLR: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Charles River Laboratories International's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Charles River Laboratories International Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Charles River Laboratories International's Cyclically Adjusted PS Ratio falls into.


CRL
70GF Score
Charles River Laboratories International Inc CRL
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Charles River Laboratories International Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Charles River Laboratories International's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=20.343/330.2130*330.2130
=20.343

Current CPI (Mar. 2026) = 330.2130.

Charles River Laboratories International Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 9.058 241.018 12.410
201609 8.863 241.428 12.122
201612 9.661 241.432 13.214
201703 9.206 243.801 12.469
201706 9.704 244.955 13.082
201709 9.594 246.819 12.836
201712 9.778 246.524 13.097
201803 10.117 249.554 13.387
201806 11.934 251.989 15.639
201809 11.866 252.439 15.522
201812 12.347 251.233 16.229
201903 12.223 254.202 15.878
201906 13.241 256.143 17.070
201909 13.436 256.759 17.280
201912 13.853 256.974 17.801
202003 14.151 258.115 18.104
202006 13.585 257.797 17.401
202009 14.660 260.280 18.599
202012 15.410 260.474 19.536
202103 16.144 264.877 20.126
202106 17.817 271.696 21.654
202109 17.377 274.310 20.918
202112 17.533 278.802 20.766
202203 17.807 287.504 20.452
202206 18.976 296.311 21.147
202209 19.288 296.808 21.459
202212 21.419 296.797 23.831
202303 20.016 301.836 21.898
202306 20.594 305.109 22.288
202309 19.893 307.789 21.342
202312 19.746 306.746 21.257
202403 19.512 312.332 20.629
202406 19.792 314.175 20.802
202409 19.575 315.301 20.501
202412 19.515 315.605 20.418
202503 19.353 319.799 19.983
202506 20.929 322.561 21.425
202509 20.330 324.800 20.669
202512 20.201 324.054 20.585
202603 20.343 330.213 20.343

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $73.42 mean?
Charles River Laboratories International (CRL) has a Cyclically Adjusted Revenue per Share of $73.42 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Charles River Laboratories International and its competitors.
Is Charles River Laboratories International's Cyclically Adjusted Revenue per Share too high?
Charles River Laboratories International's current Cyclically Adjusted Revenue per Share is $73.42. Overall, Charles River Laboratories International has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's Cyclically Adjusted Revenue per Share compare to RVTY and QGEN?
Charles River Laboratories International's Cyclically Adjusted Revenue per Share of $73.42 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Charles River Laboratories International and its competitors. Charles River Laboratories International's current Cyclically Adjusted Revenue per Share is $73.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (CRL) is currently considered Modestly Overvalued. The stock's GF Value™ is $194.04, compared to a current price of $219.40 — trading 13.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $73.42. Charles River Laboratories International's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Charles River Laboratories International (CRL), the current Cyclically Adjusted Revenue per Share is $73.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Charles River Laboratories International (CRL) Overvalued in 2026?

Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued. The current stock price of $219.40 is trading 13.1% above its estimated GF Value™ of $194.04. GuruFocus considers Charles River Laboratories International to be Modestly Overvalued.

Key valuation signals for CRL:

  • Cyclically Adjusted Revenue per Share: $73.42
  • GF Value™: $194.04 vs. price of $219.40 (13.1% above fair value)
  • GF Score™: 70/100 with 8 warning signs

No single metric tells the full story. See the CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Charles River Laboratories International Business Description

Other Exchanges RV6:Germany
Address 251 Ballardvale Street, Wilmington, MA, USA, 01887
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
70GF Score

Get the complete analysis for CRL

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$219.40
Price
$194.04
GF Value